EUCTR2012-005563-27-DE进行中（未招募）1 期
A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 203
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet ALL inclusion criteria to be eligible for the study:
- •1.Age = 18 years;
- •2.Total bilirubin = 8 mg/dL;
- •3.A clinical diagnosis of alcohol-induced liver decompensation (AILD), based upon evidence (by lab test, medical history, or family interview) of a clinical judgment of a temporal (6 weeks or less) and causal relationship between use of alcohol and this onset of symptoms;
- •4.Subjects meeting inclusion criteria 1 through 3 will be classified as having either:
- •a.Severe acute alcoholic hepatitis (AAH), with:
- •i. Medical history of alcohol abuse; AND
- •ii. Maddrey score of = 32; AND
- •iii. AAH documented by either:
- •1.Confirmatory liver biopsy, OR
- •2.Two or more of the following:
- •a.Hepatomegaly,
- •b.AST > ALT,
- •d.Leukocytosis (WBC count above lab normal at site),
- •b.Alcohol-induced decompensation of chronic liver disease that is not acute alcoholic hepatitis (as defined above), with:
- •i. MELD score of 18-35; AND
- •ii. Underlying chronic liver disease documented by:
- •1.Liver biopsy, AND/OR
- •2.Laboratory findings, AND/OR
- •3.Medical history;
- •5.Not eligible for liver transplant during this hospitalization;
- •6.Subject or legally authorized representative must provide Informed Consent;
- •7.Subject must be eligible for Standard of Care treatment as defined in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Subjects must NOT meet any of the following exclusion criteria:
- •1.Platelet count < 40,000/mm3;
- •2.International Normalization Ratio (INR) > 3.5;
- •3.MELD Score > 35;
- •4.AST > 500 IU/L;
- •5.Evidence of infection unresponsive to antibiotics;
- •6.Evidence of reduction in total bilirubin of 20% or more in the previous 72 hours, if available. Bilirubin measurements must be taken at least 12 hours after any procedure known to artificially alter serum bilirubin (e.g., administration of packed red blood cells, plasma exchange);
- •7.Evidence of hemodynamic instability as defined by the following:
- •a. Systolic blood pressure < 90 mmHg with evidence of diminished perfusion unresponsive to fluid resuscitation and/or low-dose pressor support; OR
- •b. Mean arterial pressure (MAP) < 60 mmHg with evidence of diminished perfusion unresponsive to fluid resuscitation and/or low-dose pressor support; OR
- •c. Requirement for escalating doses of vasopressor support prior to Screening; OR
- •d. Subject at maximum vasopressor dose at Screening;
- •8.Evidence of active bleeding or of major hemorrhage defined as requiring = 2 units packed red blood cells to maintain a stable hemoglobin occurring within 48 hours of Screening;
- •9.Clinical evidence of liver size reduction due to cirrhosis (liver size of craniocaudal diameter [sagittal view] < 10 cm when measured laterally on the mid clavicular line (or equivalent measurement) by ultrasound, or liver volume < 750 cc as determined by CT), unless Investigator interpretation of the clinical evidence indicates liver size of < 10 cm or volume < 750 cc is not considered reduced for the individual subject;
- •10.Occlusive portal vein thrombosis impairing hepatopetal flow, or evidence of bile duct obstruction;
- •11.Evidence by physical exam, history, or laboratory evaluation, of significant concomitant disease with expected life expectancy of less than 3 months, including, but not limited to:
- •a. Severe acute or chronic cardiovascular, central nervous system, or pulmonary disease;
- •b. Cancer that has metastasized or has not yet been treated;
- •12.Subject has chronic end-stage renal disease requiring chronic hemodialysis for more than 8 weeks (not classified as hepatorenal syndrome);
- •13.Subject has liver disease related to homozygous hemachromotosis, Wilson’s Disease, has non-alcoholic fatty liver disease, or Budd-Chiari Syndrome;
- •14.Pregnancy as determined by ß-human chorionic gonadotropin (HCG) results, or lactation;
- •15.Participation in another investigational drug, biologic, or device study within one month of enrollment, except for observational studies;
- •16.Previous liver transplant;
- •17.Previous enrollment in the treatment phase of another ELAD trial (e.g. subject is not disqualified from enrollment in VTI-208 if they were screened for VTI-210 but did not qualify for enrollment in the treatment phase of the study and therefore did not receive ELAD or Control treatment);
- •18.Have a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive (or such local equivalent) or any other Advanced Directive limiting Standard of Care in place;
- •19.Refusal to participate in the VTI-208E follow-up study;
- •20.Inability to provide an address for home visits.
研究者
相似试验
进行中（未招募）
不适用
A STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)EUCTR2012-005563-27-ESVITAL THERAPIES INCORPORATED200
进行中（未招募）
1 期
The study examines the safety and efficacy of ELAD treatment as acontinuous liver support to a subject with compromised liver functionowing to severe acute alcoholic hepatitis who are Lille score failures (Lille score >0.45), allowing time for the subject's native liver to regenerate to a healthy state. The primary objective is to evaluate safety and efficacy with respect to overall survival of subjects through study termination (after last surviving enrolled subject completes Study Day 91).Severe Acute Alcoholic Hepatitis (sAAH)MedDRA version: 18.0Level: PTClassification code 10019755Term: Hepatitis chronic activeSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2013-001884-21-GBVITAL THERAPIES INCORPORATED150
进行中（未招募）
不适用
Study examines the safety and efficacy of ELAD treatment as a continuous liver support to a subject with compromised liver function owing to severe acute alcoholic hepatitis who is a Lille score failure (Lille score >0.45), allowing time for the subject's native liver to regenerate to a functional state. The primary objective is to evaluate safety and efficacy with respect to overall survival of subjects through study termination (after last surviving enrolled subject completes Study Day 91).EUCTR2013-001884-21-ATVITAL THERAPIES, INC.150
进行中（未招募）
不适用
This study examines the safety and efficacy of using ELAD therapy as a continuous liver support in subjects with compromised liver function owing to severe acute alcoholic hepatitis (sAAH), allowing time for the subject's native liver to regenerate to a healthy state. The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival (OS) of subjects through VTI-210 study termination (after the last surviving enrolled subject completes study day 91)EUCTR2013-001884-21-DEVITAL THERAPIES, INC.150
进行中（未招募）
不适用
This study examines the safety and efficacy of using ELAD treatment as a continuous liver support to a subject with compromised liver function owing to alcohol-induced liver decompensation, allowing time for the subject's native liver to regenerate to a healthy state. The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival (OS) of subjects up to at least Study Day 91.EUCTR2012-005563-27-GBVital Therapies, Inc.200